Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

revumenib citrate

(reh-VOO-meh-nib SIH-trayt)
A drug used to treat adults and children aged 1 year and older with acute leukemia that has a certain change in the KMT2A gene and has come back or has not gotten better with other treatment. It is also being studied in the treatment of other types of cancer. Revumenib citrate binds to a protein called menin and keeps it from binding to another protein called KMT2A. This stops or slows the growth of leukemia cells with changes in the KMT2A gene. Also called Revuforj.
More Information
Search NCI's Dictionary of Cancer Terms